thalidomide has been researched along with Nephrotic Syndrome in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Nephrotic Syndrome: A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We presented a very rare case report describing the successful treatment of LCDD (λ chain)-induced nephrotic syndrome with lenalidomide." | 7.88 | Successful treatment of nephrotic syndrome induced by lambda light chain deposition disease using lenalidomide: A case report and review of the literature . ( Mima, A; Nagahara, D; Tansho, K, 2018) |
| "Considering the involvement of IL-6 in Castleman's disease we treated the patient with thalidomide obtaining the remission of the nephrotic syndrome." | 5.32 | Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease. ( Canelles, MF; Menegato, MA; Pizzolitto, S; Tonutti, E, 2004) |
| "We presented a very rare case report describing the successful treatment of LCDD (λ chain)-induced nephrotic syndrome with lenalidomide." | 3.88 | Successful treatment of nephrotic syndrome induced by lambda light chain deposition disease using lenalidomide: A case report and review of the literature . ( Mima, A; Nagahara, D; Tansho, K, 2018) |
| " Data about BNP dosage for cardiovascular monitoring of patients with ALA on renal replacement therapy are lacking." | 1.33 | Role of B-type natriuretic peptide in cardiovascular state monitoring in a hemodialysis patient with primary amyloidosis. ( Cantelli, S; Catizone, L; Fabbian, F; Molino, C; Russo, G; Russo, M; Sartori, S; Stabellini, N, 2006) |
| "Considering the involvement of IL-6 in Castleman's disease we treated the patient with thalidomide obtaining the remission of the nephrotic syndrome." | 1.32 | Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease. ( Canelles, MF; Menegato, MA; Pizzolitto, S; Tonutti, E, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mima, A | 1 |
| Nagahara, D | 1 |
| Tansho, K | 1 |
| De Lazzari, M | 1 |
| Fedrigo, M | 1 |
| Migliore, F | 1 |
| Cianci, A | 1 |
| Cacciavillani, L | 1 |
| Tarantini, G | 1 |
| Giorgi, B | 1 |
| Iliceto, S | 1 |
| Thiene, G | 1 |
| Valente, M | 1 |
| Angelini, A | 1 |
| Adami, F | 1 |
| Perazzolo Marra, M | 1 |
| Fujita, H | 1 |
| Hishizawa, M | 1 |
| Sakamoto, S | 1 |
| Kondo, T | 1 |
| Kadowaki, N | 1 |
| Ishikawa, T | 1 |
| Itoh, J | 1 |
| Fukatsu, A | 1 |
| Uchiyama, T | 1 |
| Takaori-Kondo, A | 1 |
| HUTCHISON, JH | 1 |
| Menegato, MA | 1 |
| Canelles, MF | 1 |
| Tonutti, E | 1 |
| Pizzolitto, S | 1 |
| Fabbian, F | 1 |
| Stabellini, N | 1 |
| Sartori, S | 1 |
| Molino, C | 1 |
| Russo, G | 1 |
| Russo, M | 1 |
| Cantelli, S | 1 |
| Catizone, L | 1 |
| Ramadan, KM | 1 |
| McKenna, KE | 1 |
| Morris, TC | 1 |
| Hoyer, RJ | 1 |
| Leung, N | 1 |
| Witzig, TE | 1 |
| Lacy, MQ | 1 |
8 other studies available for thalidomide and Nephrotic Syndrome
| Article | Year |
|---|---|
Successful treatment of nephrotic syndrome induced by lambda light chain deposition disease using lenalidomide: A case report and review of the literature
.
Topics: Aged, 80 and over; Female; Humans; Immunoglobulin lambda-Chains; Immunologic Factors; Lenalidomide; | 2018 |
Nonamyloidotic Light Chain Cardiomyopathy: The Arrhythmogenic Magnetic Resonance Pattern.
Topics: Bortezomib; Cardiomyopathies; Combined Modality Therapy; Defibrillators, Implantable; Dexamethasone; | 2016 |
Durable hematological response and improvement of nephrotic syndrome on thalidomide therapy in a patient with refractory light chain deposition disease.
Topics: Adult; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immun | 2011 |
Advances in paediatrics.
Topics: Child; Drug Therapy; Humans; Leukemia; Nephrotic Syndrome; Pediatrics; Phenylketonurias; Thalidomide | 1962 |
Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease.
Topics: Aged; Biopsy; Castleman Disease; Female; Glomerulonephritis, Membranoproliferative; Humans; Immunosu | 2004 |
Role of B-type natriuretic peptide in cardiovascular state monitoring in a hemodialysis patient with primary amyloidosis.
Topics: Amyloidosis; Anti-Inflammatory Agents; Bicarbonates; Buffers; Cardiac Output, Low; Follow-Up Studies | 2006 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bor | 2006 |
Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis.
Topics: Amyloidosis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Captopril; Ches | 2007 |